Prior to the most recent BTD of Gilead's TrodelvyÂ

Prior to the most recent BTD of Gilead's Trodelvy® (sacituzumab govitecan), it was:

Under current Standard of Care, these cancer biomarkers, CAML and CTC typically return back to their elevated Cancer levels around the 2 month point following treatment. When the CAML and CTC biomarkers are at these higher levels, they indicate: Active Proliferating Cancer.

Trodelvy raised it to:

Quote:

---

The EC’s decision is supported by results from the Phase 3 ASCENT study, where Trodelvy reduced the risk of death by 49% and improved median overall survival to 11.8 months versus 6.9 months with physician’s choice of chemotherapy (HR: 0.51; 95% CI: 0.41-0.62; p<0.0001). These data also showed a statistically significant and clinically meaningful 57% reduction in the risk of death or disease worsening and improved median progression free survival (PFS) to 4.8 months from 1.7 months seen with physician’s choice of chemotherapy alone among all randomized patients, which included those with and without brain metastases (HR: 0.43; 95% CI: 0.35-0.54; p<0.0001).

---

taken from: https://www.gilead.com/news-and-press/press-r...cer-in-sec

11.8 - 4.8 = 7 months. That's how long the patients lived on average once their cancer returned and came out of remission. Trodelvy bought them 4.8 months of remission, that's it. The rest was hanging on.

That means if we have an OS of 12.5 months, and our PFS was also 12 months, (return to normal life), then we can safely add another 7 months, (if LL was dc'd immediately and the cancer went out of remission exactly then) to our current OS of 12 and come up with an anecdotal 19 months OS for LL without the data to prove it.